Valuation: Natera, Inc.

Market Cap 48.53B 41.59B 38.97B 35.6B 67.18B 4,627B 67.84B 460B 179B 2,334B 182B 178B 7,731B P/E 2026 *
-246x
P/E 2027 * -39,152x
Enterprise Value 47.47B 40.67B 38.11B 34.81B 65.7B 4,525B 66.35B 450B 175B 2,283B 178B 174B 7,561B EV / Sales 2026 *
16.3x
EV / Sales 2027 * 13.6x
Free-Float
97.12%
Yield 2026 *
-
Yield 2027 * -
1 day+2.74%
1 week+8.03%
Current month+25.75%
1 month+28.52%
3 months+65.71%
6 months+58.95%
Current year+46.98%
1 week 320
Extreme 320
337.12
1 month 248.03
Extreme 248.0275
337.12
Current year 181
Extreme 181
337.12
1 year 157.42
Extreme 157.425
337.12
3 years 36.9
Extreme 36.9
337.12
5 years 26.1
Extreme 26.1
337.12
10 years 7.35
Extreme 7.35
337.12
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Founder

-6,000 0.0042%
07/08/26 Sell

Founder

-2,000 0.0014%
07/08/26 Sell

Founder

-9,150 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%+8.03%+107.24%+486.81% 48.53B
-0.49%+4.81%+22.30%+59.14% 27.39B
-1.86%-14.86%-15.86%-37.72% 7.23B
+2.91%+4.10%+10.45%+139.44% 6.05B
+1.00%+2.46%+16.89%+76.86% 3.35B
+2.60%+14.49%-28.28%+1,956.59% 2.61B
+2.32%+5.60%+160.31%+20.62% 2.16B
-1.45%+1.24%-7.80%-51.91% 2.02B
+0.38%+3.27%+31.36%+24.18% 1.97B
-1.82%-4.93%+17.02%-10.36% 1.77B
Average +0.64%+3.47%+31.36%+266.36% 10.31B
Weighted average by Cap. +1.30%+5.18%+59.85%+302.17%

Financials

2026 *2027 *
Net sales 2.91B 2.49B 2.33B 2.13B 4.02B 277B 4.06B 27.51B 10.71B 140B 10.91B 10.67B 463B 3.48B 2.98B 2.79B 2.55B 4.82B 332B 4.86B 32.96B 12.83B 167B 13.07B 12.78B 554B
Net income -193M -165M -155M -142M -267M -18.39B -270M -1.83B -711M -9.28B -724M -709M -30.73B 9.13M 7.82M 7.33M 6.69M 12.63M 870M 12.76M 86.45M 33.66M 439M 34.27M 33.53M 1.45B
Net Debt -1.07B -915M -858M -783M -1.48B -102B -1.49B -10.12B -3.94B -51.38B -4.01B -3.92B -170B -1.36B -1.17B -1.09B -1B -1.89B -130B -1.91B -12.91B -5.03B -65.56B -5.12B -5.01B -217B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
25/08/26 $336.71 +2.74% 1,733,153
24/08/26 $327.72 -1.30% 1,219,524
21/08/26 $332.03 +2.21% 1,215,079
20/08/26 $324.84 -0.07% 1,738,495
19/08/26 $325.07 +4.29% 1,792,088
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
336.71USD
Average target price
336.74USD
Spread / Average Target
+0.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock